#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Transfusion and Haematology Today / 2020 - 2

Castleman disease, one of the causes of chronic systemic inflammatory response as well as fluid retention, vasculitis and immune disorders sometimes – international criteria, 2017

Czech version

Authors: Z. Král 1;  Z. Adam 1;  P. Volfová 2;  M. Ježová 3;  M. Krejčí 1;  L. Pour 1;  Z. Řehák 4,5;  R. Koukalová 4
Authors‘ workplace: Interní hematologická a onkologická klinika LF MU a FN Brno 1;  Interní hematologická a onkologická klinika – Centrum molekulární biologie a genové terapie, sekce oportunních infekcí, Dětská nemocnice 2;  Ústav patologie LF MU a FN Brno, Jihlavská 25, 625 00 Brno 3;  Oddělení nukleární medicíny, Masarykův onkologický ústav 4;  Regionální centrum aplikované molekulární onkologie (RECAMO), Masarykův onkologický ústav 5
Published in: Transfuze Hematol. dnes,26, 2020, No. 2, p. 92-100.
Category: Review/Educational Papers

Overview

Castleman disease was first described more than 60 years ago. It is a rare and heterogenic group of diseases characterised by lymphadenopathy with typical morphological features associated with general inflammatory symptoms and laboratory deviations.

The first international diagnostic criteria of this disease were published in 2017 and are detailed in this article. In the USA, the incidence of this diseases is estimated at 5/1 million inhabitants. The incidence in the Czech Republic has not been determined as yet. However, it is possible that some cases are considered to represent a systemic inflammatory response of unknown origin and are thus not diagnosed properly. The aim of this text is to recapitulate the manifestations of this disease and present the first international diagnostic criteria published in 2017. 

Keywords:

rituximab – Castleman disease – POEMS syndrome – TAFRO syndrome – lenalidomid – siltuximab – anakinra – thalidomid

Sources
  1. Dispenzieri A. Castleman disease. Cancer Treat Res. 2008;142:293–330.
  2. Liu AY, Nabel CS, Finkelman BS, et al. Idiopathic multicentric Castleman´s disease: a systematic literature review. Lancet Haematol. 2016;3(4):e163–e175.
  3. Chan Kah-Lok, Lade S, Prince HM, et al. Update and new approaches in the threatment of Castleman disease. J Blood Med. 2016; 7:145–158.
  4. Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646–1657.
  5. Simpson D. Epidemiology of Castleman disease. Hematol Oncol Clin North Am. 2018;32(1):1–10.
  6. Castleman B, Towe VW. Case report of the Massachusetts General Hospital weekly clinicopathological exercises, fouded by Richard C. Cabot. N Engl J Med. 1954;251(10):396–400.
  7. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other localisation. Cancer. 1972;29:670–683.
  8. Gaba AR, Stein RS, Sweet DJ, et al. Multicentric giant node hyperplasia. Amer J Clin Pathol. 1978;69(1):86–90.
  9. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi´s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman´s disease. Blood. 1995;86(4):1276–1280.
  10. Chadbum A, Cesarman E, Nador RG, et al. Kaposi´s sarcoma-associated herpesvirus sequences in benign lymphoid proliferations not associated with human immunodeficiency virus. Cancer. 1997;80:788–797.
  11. Riu P, Noesl LH, Droz D, et al. Glomerular involvement in lymfoproliferative disorders with hyperproduction of cytokines (Castleman, POEMS). Adv Nephrol Necke Hosp. 2000;30:305–331.
  12. Masaki Y, Nakajima A, Iwao H, et al. Japanese variant of multicentric Castleman´s disease associated with serositis and thrombocytopenia – a report of two cases: is TAFRO syndrome (Castleman-Kojima disease) a distinct clinicopathological entity? J Clin Exp Hepatopathol. 2013;53(1):79–85.
  13. Kawabata H, Takai K, Kojima M, et al. Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly. J Clin Exp Hematop. 2013;53(1):57–61.
  14. Inoue M, Ankou M, Hua J, at al. Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A: a case report. J Clin Exp Hepatopathol. 2013;53(1):95–99.
  15. Tedesco S, Postacchini L, Manfredi L, et al. Successful treatment of a Caucasian case of multifocal Castleman´s disease with TAFRO syndrome with pathophysiology targeted therapy – case report. Exp Hematol Oncol. 2015;4(1):3–10.
  16. Masaki Y, Kawabata H, Takai K, et al. Proposed diagnostic criteria, disease severity classification and treatment stratedy for Tafro syndrome, 2015 version. Int J Hematol. 2016;103:686–692.
  17. Robinson D Jr, Reynolds M, Casper C, et al. Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres. Br J Haematol. 2014;165(1):39–48.
  18. Fajgenbaum DC, van Rhee F, Nabel ChS. HHV-8 negative idiopathic multicentric Castleman disease: novel insight into biology pathogenesis and therapy. Blood. 2014;123(19):2924–2933.
  19. Bower M, Pria AD, Coyle C, et al. Diagnostic criteria schemes for multicentric Castleman disease in 75 cases. J Acquir Immune Defic Syndr. 2014;65(2):e80–e82.
  20. Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009;16:236–246.
  21. Kawabata H, Kadowaki N, Nishikori M, et al. Clinical features and treatment of multicentric Castleman‘s disease: a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hepatopathol. 2013;53(1):69–77.
  22. El Karoui K, Vuiblet V, Dion D, et al. Renal involvement in Castleman disease. Nephrol Dial Transplant. 2011;26(2):599–609.
  23. Sydor A, Madura M, Wagrowska-Danilewicz M. Amyloid A amyloidosis and renal failure in a course of Castleman disease. Nephrology (Carlton) 2007;12(6):620–621.
  24. Leung KT, Wong KM, Choi KS, et al. Multiicentric Castleman´s disease complicated by secondary renal amyloidosis. Nephrology (Carlton). 2004;9(6):392–393.
  25. Dispenzieri A. POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89(2):214–223.
  26. Fajgenbaum DC, Rosenbach M, van Rhee F, et al. Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue. JAMA Dermatol. 2013;149(2):204–208.
  27. Ruwan KP, Parakramawansha C, Wijeweera I, et al. A case of POEMS syndrome with mixed hyaline vascular and plasma cell type Castleman´s disease. Ceylon Med J. 2009;54(2):68–69.
  28. Misri R, Kharkar V, Dandale A, et al. Multiple capillary hemangiomas: a distinctive lesion of multicentric Castleman‘s disease and POEMS syndrome. Indian J Dermatol Venereol Leprol. 2008;74(4):364–366.
  29. Garcia T, Dafer R, Hocker S, et al. Recurrent strokes in two patients with POEMS syndrome and Castleman´s disease. J Stroke Cerebrovasc Dis. 2007;16(6):278–284.
  30. Eisenbarth SC, Colegio OR, Iyer A, Cooper D, Bannykh S, Baehring J. Images in neuro-oncology: a case of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein and Skin changes) in a patient with multicentric Castleman´s disease. J Neurooncol. 2007;81(2):163–165.
  31. Huang J, Wang L, Zhou W, Jin J. Hyaline vascular Castleman disease associated with POEMS syndrome and cerebral infarction. Ann Hematol. 2007;86(1):59–61.
  32. Iwaki N, Fajgenbaum DC, Nabel SCh, et al. Clinicopathological analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8 negative multicentric Castleman disease. Am J Hematol. 2016;91:220–226.
  33. Igawa T, Sato Y. TAFRO syndrome. Hematol Oncol Clin North Am. 2018;32(1):107–118.
  34. Dispenzieri A, Armitage JO, Loes MJ, et al. The clinical spectrum of Castleman´s disease. Amer J Hematol. 2012;87:997–1002.
  35. Szalat R, Munshi NC. Diagnosis of Castleman disease. Hematol Oncol Clin North Am. 2018;32(1):53–64.
  36. van Rhee F, Voorhees P, Dispenzieri A, et al. International evidence based consensus treatment guidelines for idiopahtic multicentric Castleman disease. Blood. 2018;132(20):2115–2124.
Labels
Haematology Internal medicine Clinical oncology
Editorial
Thrombotic microangiopathies
Treatment of Langerhans cell histiocytosis in adults
The last days of patients with non-Hodgkin’s lymphoma - analysis of a sample of deceased patients over a period of 6 years (2012-2017) at one institution and the role of integrating palliative care
Storing red cells at non-standard temperature
Theralite and multiple myeloma – do we know the answer regarding treatment efficacy of a nephrologist with a haematologist?
Surprising findings in the bone marrow: what lies behind it?
Životní jubileum pana profesora Jiřího Mayera
Article was published in

Transfusion and Haematology Today

Issue 2
2020 Issue 2
Most read in this issue
Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#